Lv1
58 积分 2023-01-26 加入
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
1个月前
已关闭
Anti-angiogenesis enhances the tumor immunotherapeutical effect of recombinant CD80 fusion protein
2个月前
已完结
Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia
5个月前
已完结
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial
5个月前
已完结
To platform or not to platform: Strategic considerations for antibody formulation in early clinical development
6个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
6个月前
已完结
Recent progress in ITP treatment
6个月前
已完结
LILRB4 as a novel immunotherapeutic target for multiple diseases
9个月前
已完结
Secretogranin 2 binds LILRB4 resulting in immunosuppression
9个月前
已完结
LILRB4 specific overexpression in myeloid cells promotes tumor progression and immunosuppression in mouse models
9个月前
已完结
皖公网安备34019202002308
